Two law-firm press releases on July 20, 2026 state that Regeneron Pharmaceuticals, Inc. is facing a securities class action alleging securities law violations. Both releases say the lawsuit claims violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5. The PR Newswire notices do not provide details about the underlying allegations, the specific events at issue, or the procedural status of the case. Instead, they focus on investor actions, including urging Regeneron shareholders who may be affected to contact the firms for information about potential rights in the litigation. One release promotes outreach by DJS Law Group, while the other promotes outreach by the Schall Law Firm, describing their respective roles in shareholder rights litigation. Neither source presents company responses or commentary in the releases, and the articles do not confirm outcomes or judgments. Overall, the reporting centers on the existence of the class action and the firms’ solicitation of potentially eligible investors to participate or learn more about the case.